SLC2A1 and neoplasm: We used the PI3K/AKT inhibitor LY294002 to block the PI3K/AKT pathway and found that LY294002 significantly suppressed tumour growth and down‐regulated expression of GLUT1, HK II and LDHA in cells overexpressing SLC1A3.